The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than March 1, 1991.

A. Federal Reserve Bank of Kansas City (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. Texhoma Bancshares, Inc., Texhoma, Oklahoma; to become a bank holding company by acquiring 93.9 percent of the voting shares of The First National Bank of Texhoma, Texhoma, Oklahoma.

Board of Governors of the Federal Reserve System, February 5, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 91-3136 Filed 2-8-91; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Alcohol, Drug Abuse, and Mental Health Administration

Advisory Committee Meetings in February–March

AGENCY: Alcohol, Drug Abuse, and Mental Health Administration, HHS.

ACTION: Correction of meeting notices.

SUMMARY: Public notice was given in the **Federal Register** on January 11, 1991, Volume 56, No. 8, on page 1195 that the Biological and Neurosciences Subcommittee of the Mental Health Small Grant Review Committee, NIMH, would meet February 20–22. The Committee will meet February 21–22. On February 21 the meeting will be open from 9–10 a.m.; the remainder of the meeting will be closed.

Public notice was also given in the **Federal Register** on January 11, 1991, Volume 56, No. 8, on page 1196 that the Immunology and AIDS Subcommittee of the Alcohol Biomedical Research Review Committee, NIAAA, would meet February 28–March 1. The Committee will meet only on March 1. The meeting will be open from 9–10 a.m.; the remainder of the meeting will be closed.

Dated: February 6, 1991.

Peggy W. Cockrill,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration

[FR Doc. 91-3228 Filed 2-8-91; 8:45 am]

BILLING CODE 4160-20-M

Advisory Committee Meetings in March

AGENCY: Alcohol, Drug Abuse, and Mental Health Administration, HHS.

ACTION: Notice of meetings.

SUMMARY: This notice sets forth the schedule and proposed agendas of the forthcoming meetings of the agency's advisory committees in the month of March 1991.

The Extramural Science Advisory Board, NIAAA, will discuss the current research activities of the Institute and other business of the Board. Attendance by the public will be limited to space available.

The initial review committees will be performing initial review of applications for Federal assistance. Therefore, portions of the meetings will be closed to the public as determined by the Administrator, ADAMHA, in accordance with 5 U.S.C. 552(b)(6) and 5 U.S.C. app. 2 10(d).

Notice of thee meetings is required under the Federal Advisory Committee Act, Public Law 92–463.

* * * * *

Committee Name: Psychosocial and Biobehavioral Treatments Subcommittee of the Treatment Development and Assessment Research Review Committee, NIMH.

Date and Time: March 4–5: 9 a.m.

Place: Vista International Hotel, 1400 M Street, NW., Washington, DC 20036.

Status of Meeting: Open—March 4: 9–10 a.m. Closed—otherwise.

Contact: Frances Smith, room 9C–02, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–4868.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research and/or research training activities in the area of treatment development and assessment and makes recommendations to the National Advisory Mental Health Council for final review.

* * * * *

Committee Name: Clinical, Psychosocial, and Behavioral Sciences Subcommittee of the Mental Health Acquired Immunodeficiency Syndrome Research Review Committee, NIMH.

Date and Time: March 6–7: 8:30 a.m.

Place: The Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Status of Meeting: Open—March 6: 8:30–9:15 a.m. Closed—otherwise.

Contact: Regina Thomas, Room 9C–15, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–6470.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research activities in the areas of clinical, psychosocial, and behavioral sciences aspects of AIDS as they relate to mental health, and makes recommendations to the National Advisory Mental Health Council for final review.

* * * * *

Committee Name: Psychobiological, Biological, and Neurosciences Subcommittee of the Mental Health Acquired Immunodeficiency Syndrome Research Review Committee, NIMH.

Date and Time: March 6–7: 8:30 a.m.

Place: The Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Status of Meeting: Open—March 6: 8:30–9:15 a.m. Closed—otherwise.

Contact: Regina Thomas, room 9C–15, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–6470.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research activities in the areas of psychobiological, biological, and neurosciences aspects of AIDS as they relate to mental health, and makes recommendations to the National Advisory Mental Health Council for final review.

* * * * *

Committee Name: Extramural Science Advisory Board, NIAA.

Date and Time: March 11–12: 8:30 a.m.

Place: Guest Quarters, Calvert Room, 7335, Wisconsin Avenue, Bethesda, MD 20814.

Status of Meeting: Open—March 11 and 12: 8:30 a.m.–5 p.m.

Contact: Michael J. Lewis, Room 16C–14, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–6106.

Purpose: The Board advises the Director, National Institute on Alcohol Abuse and Alcoholism, the

Administrator, Alcohol, Drug Abuse, and Mental Health Administration, and the Secretary, Department of Health and Human Services, based on an ongoing review, on the direction, scope, balance, and emphasis of the National Institute on Alcohol Abuse and Alcoholism's extramural science program.

* * * * *

Committee Name: Biobehavioral/Clinical Subcommittee of the Drug Abuse AIDS Research Review Committee, NIDA.

Date and Time: March 12–14: 9 a.m.

Place: Congressional Park Days Inn, Georgetown I and II Conference Rooms, 1775 Rockville Pike, Rockville, MD 20852.

Status of Meeting: Open—March 12: 9–9:30 a.m. Closed—otherwise.

Contact: Iris W. O'Brien, Room 10–42, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–2620.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute on Drug Abuse for support of research and research training activities and makes recommendations to the National Advisory Council on Drug Abuse for final review.

* * * * *

Committee Name: Sociobehavioral Subcommittee of the Drug Abuse AIDS Research Review Committee, NIDA.

Date and Time: March 12–14: 9 a.m.

Place: Congressional Park Days Inn, Montrose I and II Conference Rooms, 1775 Rockville Pike, Rockville, MD 20852.

Status of Meeting: Open—March 12: 9–9:30 a.m. Closed—otherwise.

Contact: H. Noble Jones, Room 10–22, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–9042.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute on Drug Abuse for support of research and research training activities and makes recommendations to the National Advisory Council on Drug About for final review.

* * * * *

Committee Name: Clinical Program Projects and Clincial Research Centers Subcommittee of the Treatment Development and Assessment Research Review Committee, NIMH.

Date and Time: March 14–15: 9 a.m.

Place: Vista International Hotel, 1400 M Street, NW., Washington, DC 20036.

Status of Meeting: Open—March 14: 9–10 a.m. Closed—otherwise.

Contact: Frances Smith, Room 9C–02, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, (301) 443–4868.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of Mental Heath Clinical Research Centers, clinical program projects, and other large-scale multi-disciplinary research projects, and makes recommendations to the National Advisory mental Health Council for final review.

Substantive information, summaries of the meetings, and rosters of committee members may be obtained as follows: Ms. Diana Widner, NIAAA Committee Management Officer, room 16C–20, (301) 443–4375; Ms. Camilla Holland, NIDA Committee Management Officer Room 10–42, (301) 443–2755; Ms. Joanna Kieffer, NIMH Committee Management Officer, room 9–105, (301) 443–4333. The mailing address for the above parties is: Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

Dated: February 6, 1991.

Peggy W. Cockrill,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 91–3229 Filed 2–8–91; 8:45 am]

BILLING CODE 4160–20–M

Food and Drug Administration

Board of Tea Experts: Rechartering

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the rechartering of the Board of Tea Experts by the Commissioner of Food and Drugs. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (5 U.S.C. app. 2).

DATES: Authority for this board will expire on January 3, 1993, unless the Commissioner formally determines that rechartering is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–306), Food and Drug Administraiton, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: January 6, 1991.

Gary Dykstra,

Acting Association Commissioner for Regulatory Affairs.

[FR Doc. 91–3230 Filed 2–8–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 91F–0023]

Eastman Chemicals Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Eastman Chemicals Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2,2'-(1,2-ethenediyldi-4,1-phenylene)bis(benzoxazole) as an optical brightener for food-contact polymers.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) [21 U.S.C. 348(b)(5)]), notice is given that a petition (FAP 1B4240) has been filed by Eastman Chemicals Co., Eastman Kodak Co., P.O. Box 511, Kingsport, TN 37662, proposing that the food additive regulations in § 178.3297 *Colorants for polymers* (21 CFR 178.3297) be amended to provide for the safe use of 2,2'-(1,2-ethenediyldi-4,1-phenylene)bis(benzoxazole) as an optical brightener for food-contact polymers.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: January 31, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–3140 Filed 2–8–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 91N–0034]

Drug Export; Nitroglycerin Transdermal System 5 & 10 MG Delivered/24 Hours

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing

that Hercon Labs has filed an application requesting approval for the export of the human drug Nitroglycerin Transdermal System 5 & 10 mg Delivered/24 Hours to Spain.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, room 4–62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Frank R. Fazzari, Division of Drug Labeling Compliance (HFD–313), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Hercon Laboratories Corporation, P.O. Box 786, York, PA 17405, has filed an application requesting approval for the export of the drug Nitroglycerin Transdermal System 5 & 10 mg Delivered/24 Hours, to Spain. This drug is indicated for use in the treatment of angina pectoris prophylaxis due to coronary insufficiency. The application was received and filed in the Center for Drug Evaluation and Research on December 7, 1990, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by February 21, 1991, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: January 28, 1991.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 91–3139 Filed 2–8–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 91N–0017]

Merrell Dow Pharmaceuticals, Inc., et al.; Withdrawal of Approval of Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 70 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: March 13, 1991.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–360), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8038.

SUPPLEMENTARY INFORMATION: The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

ANDA No.	Drug	Applicant
80–173	Isoniazid Tablets, 100 milligrams (mg)	Merrell Dow Pharmaceuticals, Inc., 2110 E. Galbraith Rd., P.O. Box 156300, Cincinnati, OH 45215–6300.
80–330	Isoniazid Tablets, 300 mg	Do.
80–481	Hydrocortisone Ointment, 0.5% and 1%	C&M Pharmacal, Inc., 1519 E. Eight Mile Rd., Hazel Park, MI 48030–2696.
84–423	Chlorpromazine Hydro-chloride Tables, 25 mg	Parke-Davis, Division of Warner-Lambert Co., 201 Tabor Rd., Morris Plains, NJ 07950.
84–651	Otic Solution—HC (Acetic Acid Non-aqueous 2% with Hydrocortisone 1%).	Steris Laboratories, Inc., 620 51st Ave., Phoenix AZ 85043–4705.
85–513	A-poxide Capsules (chlor-diazepoxide hydrochloride), 25 mg	Abbott Laboratories, D–491, AP10/3, Abbott Park, IL 60064.
85–517	A-poxide Capsules (chlor-diazepoxide hydrochloride USP), 5 mg	Do.
85–518	A-poxide Capsules (chlor-diazepoxide hydrochloride USP), 10 mg	Do.
85–896	Acetaminophen and Codeine Phosphate Tablets, 300 mg/30 mg	INC Pharmaceuticals, Inc., 3300 Hyland Ave., Costa Mesa, CA 92626.
85–910	Oxycodone Hydrochloride 2.5 my/APAP 500 mg Tablets	DuPont Pharmaceuticals Caribe, Inc., P.O. Box 12, Manati, PR 00701.
85–911	Oxycodone Hydrochloride 5 mg/APAP 500 mg Tablets	Do.
86–843	Nitro-Dur (Nitroglycerin) Transdermal System, 5 mg/24 hours	Key Pharmaceuticals, Inc., 200 Galloping Hill Rd., Kenilworth, NJ 07033.
86–885	Chlorpromazine Hydrochloride Tablets, 200 mg	Parke Davis
86–886	Chlorpromazine Hydrochloride Tablets, 10 mg	Do.
86–888	Chlorpromazine Hydrochloride Tablets, 100 mg	Do.
87–493	Nitro-Dur (Nitroglycerin) Transdermal System, 10 mg/24 hours	Key Pharmaceuticals, Inc.
87–494	Nitro-Dur (Nitroglycerin) Transdermal System, 7.5 mg/24 hours	Do.
87–495	Nitro-Dur (Nitroglycerin) Transdermal System, 15 mg/24 hours	Do.
87–496	Nitro-Dur (Nitroglycerin) Transdermal System, 2.5 mg/24 hours	Do.
87–570	Amitriptyline Hydro-chloride Tablets, 25 mg	Vangard Labs, Inc., North 31-E Bypass, P.O. Box K, Glasgow, KY 42141.
87–610	Hydrochlorothiazide Tablets, 50 mg	Do.
87–616	Amitriptyline Hudrochloride Tablets, 50 mg	Do.